Abstract
The HER-2/neu protein is intimately involved with normal cell proliferation and tissue growth and is extensively homologous and related to the epidermal growth factor receptor. HER-2/neu protein expression has been most intensively studied in the context of breast carcinoma, in which its amplification and overexpression correlate with the overall course of disease, and with a poor prognosis, and constitute a predictive factor of poor response to chemotherapy and endocrine therapy. In this study, we investigated the relationship between the expression of HER-2/neu and the clinicopathological characteristics of tumors, including survival. This study was performed with a view toward the future introduction of Herceptin therapy for gastric cancer patients. HER-2/neu overexpression and gene amplification was examined with semiquantitative standardized immunohistochemical staining, chromogenic in situ hybridization (CISH), and fluorescence in situ hybridization (FISH) in 182 gastric cancer patients who underwent curative surgery at the Kangbuk Samsung Hospital. Twenty-nine (15.9%) of 182 patients expressed the HER-2/neu protein by immunohistochemistry. HER-2/neu gene amplification was detected in seven patients by CISH and FISH. Intestinal-type cancers exhibited higher rates of HER-2/neu amplification than did diffuse-type cancers (P < 0.05). Tumors with HER-2/neu amplification were associated with poor mean survival rates (922 vs 3243 days) and 5-year survival rates (21.4% vs 63.0%; P < 0.05). Age, TNM stage, and amplification of HER-2/neu were found to be independently related to survival by multivariate analysis. HER-2/neu amplification may constitute an independent prognostic factor in gastric cancer patients, and patients exhibiting HER-2/neu amplification might constitute potential candidates for new adjuvant therapies which involve the use of humanized monoclonal antibodies.
Similar content being viewed by others
References
Watanabe S, Tsugane S, Ohno Y (1988) Prediction of the gastric cancer mortality in 2000 in Japan. Jpn J Cancer Res 79:439–444
Ministry of Health and Welfare and National Cancer Center (2002) Annual Report of the Korea Central Cancer Registry
Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB–2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646
Coussens L, Yang-Feng TL, Liao YC, et al. (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139
Kaptain S, Tan LK, Chen B (2001) Her–2/neu and breast cancer. Diagn Mol Pathol 10:139–152
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726
McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RCJr (1993) Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 71:3942–3946
Hirashima N, Takahashi W, Yoshii S, Yamane T, Ooi A (2001) Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 14:556–662
Cohen JA, Weiner DB, More KF, Kokai Y, Williams WV, Maguire HCJr, LiVolsi VA, Greene MI (1989) Expression pattern of the neu (NGL) gene–encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 4:81–88
Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A (1997) Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol 151:761–768
Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O’Brien M, Bensted J (1996) The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer. Eur J Cancer 32A:63–68
Orita H, Maehara Y, Emi Y, Kakeji Y, Baba H, Korenaga D, Sugimachi K (1997) c-erbB-2 expression is predictive for lymphatic spread of clinical gastric carcinoma. Hepatogastroenterology 44:294–298
Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 75(Suppl 6):1418–1425
Ooi A, Kobayashi M, Mai M, Nakanishi I (1998) Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization. Lab Invest 78:345–351
Sato T, Abe K, Kurose A, Uesugi N, Todoroki T, Sasaki K (1997) Amplification of the c-erbB-2 gene detected by FISH in gastric cancers. Pathol Int 47:179–182
Uchino S, Tsuda H, Maruyama K, Kinoshita T, Sasako M, Saito T, Kobayashi M, Hirohashi S (1993) Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 72:3179–184
Chariyalertsak S, Sugano K, Ohkura H, Mori Y (1994) Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. Tumour Biol 15:294–303
Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y (1993) Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 72:2083–2038
Hilton DA, West KP (1992) c-erbB-2 oncogene product expression and prognosis in gastric carcinoma. J Clin Pathol 45:454–456
Kolodziejczyk P, Yao T, Oya M, Nakamura S, Utsunomiya T, Ishikawa T, Tsuneyoshi M (1994) Long-term follow-up study of patients with gastric adenomas with malignant transformation. An immunohistochemical and histochemical analysis. Cancer 74:2896–2907
Tateishi M, Toda T, Minamisono Y, Nagasaki S (1992) Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 49:209–212
Sasano H, Date F, Imatani A, Asaki S, Nagura H (1993) Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 24:584–589
Sobin LH, Wittekind C (eds) (1997) TNM classification of malignant tumors, 5th ed. Wiley-Liss, New York
Fenoglio-Preiser C, Carneiro F, Correa O, et al. (2000) Tumors of the stomach. In: Hamilton SR, Aaltonen LA (eds) World Health Organization classification of tumors, pathology and genetics of tumors of the digestive system. IARC, Lyon, pp 37–52
Pauletti G, Dandekar S, Rong H, et al. (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651–3664
Yonemura Y, Ninomiya I, Ohoyama S, et al. (1991) Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 67:2914–2918
Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Miyazaki I, Endou Y, Tanaka M, Sasaki T (1991) Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 51:1034–1038
Ohguri T, Sato Y, Koizumi W, Saigenji K, Kameya T (1993) An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: Is the c-erbB-2 protein really a prognostic indicator? Int J Cancer 53:75–79
Falck VG, Gullick WJ (1989) c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. J Pathol 159:107–111
Lemoine NR, Jain S, Silvestre F, Lopes C, Hughes CM, McLelland E, Gullick WJ, Filipe MI (1991) Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 64:79–83
Seidal T, Balaton AJ, Battifora H (2001) Interpretation and quantification of immunostains. Am J Surg Pathol 25:1204–1207
Jain S, Filipe MI, Gullick WJ, Linehan J, Morris RW (1991) c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer 48:668–671
Pauletti G, Godolphin W, Press MF, Slamon DJ (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63–72
Kameda T, Yasui W, Yoshida K, Tsujino T, Nakayama H, Ito M, Ito H, Tahara E (1990) Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 50:8002–8029
Kraus MH, Popescu NC, Amsbaugh SC, King CR (1987) Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6:605–610
Hollywood DP, Hurst HC (1993) A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 12:2369–2375
Slamon DJ, Godolphin W, Jones LA, et al.(1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712
Joh JW, Noh DY, Bae CD, Choi KJ, Park JB (1996) Amplification and over-expression of erbB–2 oncogene in primary human breast tumors. Exp Mol Med 28:47–53
Schnitt SJ (2001) Breast cancer in the 21st century: new opportunities and new challenges. Mod Pathol 14:213–218
Acknowledgement
This study was supported by Samsung Biomedical Research Institute Grant SBRI C-A4-212-1.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Park, D.I., Yun, J.W., Park, J.H. et al. HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer. Dig Dis Sci 51, 1371–1379 (2006). https://doi.org/10.1007/s10620-005-9057-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-005-9057-1